These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Analysis of the Middlebrooks CD; Stacey ML; Li Q; Snyder C; Shaw TG; Richardson-Nelson T; Rendell M; Ferguson C; Silberstein P; Casey MJ; Bailey-Wilson JE; Lynch HT Cancer Res; 2019 Jun; 79(11):2992-3000. PubMed ID: 30967399 [TBL] [Abstract][Full Text] [Related]
24. CDKN2A germline mutations in familial pancreatic cancer. Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511 [TBL] [Abstract][Full Text] [Related]
25. Multiple primary melanoma revisited. Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124 [TBL] [Abstract][Full Text] [Related]
26. Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant. Potjer TP; Kranenburg HE; Bergman W; de Vos tot Nederveen Cappel WH; van Monsjou HS; Barge-Schaapveld DQ; Vasen HF Eur J Hum Genet; 2015 May; 23(5):711-4. PubMed ID: 25227142 [TBL] [Abstract][Full Text] [Related]
28. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182 [TBL] [Abstract][Full Text] [Related]
29. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation. van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584 [TBL] [Abstract][Full Text] [Related]
30. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers. Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143 [TBL] [Abstract][Full Text] [Related]
31. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799 [TBL] [Abstract][Full Text] [Related]
32. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885 [TBL] [Abstract][Full Text] [Related]
34. High Growth Rate of Pancreatic Ductal Adenocarcinoma in Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580 [No Abstract] [Full Text] [Related]
35. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer. De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703 [TBL] [Abstract][Full Text] [Related]
36. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833 [No Abstract] [Full Text] [Related]
37. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Celebi JT; Ward KM; Wanner M; Polsky D; Kopf AW Clin Exp Dermatol; 2005 Jan; 30(1):68-70. PubMed ID: 15663508 [TBL] [Abstract][Full Text] [Related]
38. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. Hansson J; Bergenmar M; Hofer PA; Lundell G; Månsson-Brahme E; Ringborg U; Synnerstad I; Bratel AT; Wennberg AM; Rosdahl I J Clin Oncol; 2007 Jul; 25(19):2819-24. PubMed ID: 17602087 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189 [TBL] [Abstract][Full Text] [Related]
40. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. Hashemi J; Linder S; Platz A; Hansson J Melanoma Res; 1999 Feb; 9(1):21-30. PubMed ID: 10338331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]